U.S. Energy Services Stock News

NasdaqGS:NTAP
NasdaqGS:NTAPTech

Does The Recent Pullback Make NetApp (NTAP) Look Attractive On Valuation Grounds?

If you are wondering whether NetApp's share price really reflects what the business is worth today, you are not alone. That is exactly what this article will unpack. NetApp shares last closed at US$98.66, with returns of 9.5% over 1 year, 71.3% over 3 years and 58.3% over 5 years. However, the stock has seen a 2.4% decline over 7 days, 6.8% over 30 days and 7.3% year to date. Recent company specific headlines have continued to keep investor attention on NetApp, helping frame how the market...
NasdaqGS:MAPS
NasdaqGS:MAPSSoftware

WM Technology (MAPS) Margin Compression To 1.1% Tests Bullish Earnings Narratives

WM Technology (MAPS) closed out FY 2025 with Q4 revenue of about US$43.1 million and a basic EPS loss of roughly US$0.03, while trailing twelve month EPS stood at around US$0.02 on revenue of roughly US$174.7 million. Over recent periods the company has seen quarterly revenue range between about US$42.2 million and US$47.7 million, with EPS moving from a profit of roughly US$0.03 per share in late 2024 to small profits through most of 2025 before the latest quarterly loss. This has left...
NYSE:MC
NYSE:MCCapital Markets

Is It Time To Revisit Moelis (MC) After The Recent Share Price Slump

If you are wondering whether Moelis shares offer good value at today's price, it helps to step back and look at what the current market is implying about the business. The stock last closed at US$51.75, after a 7.8% decline over the past week, a 25.1% decline over the past month, and a 27.3% decline year to date, while still showing a 51.6% return over 3 years and 23.6% over 5 years. These recent moves have kept Moelis on investors' radars, with market commentary often linking advisory firms...
NasdaqCM:IMUX
NasdaqCM:IMUXBiotechs

Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition?

Immunic, Inc. recently secured a key European patent for its lead asset vidofludimus calcium, aligning protection with existing U.S. coverage and potentially extending exclusivity into the 2040s for chronic inflammatory and autoimmune indications. This expanded intellectual property protection materially underpins the company’s core therapeutic franchise by lengthening its runway to develop and, if approved, commercialize its main clinical asset. Against this backdrop, we’ll explore how the...
NasdaqCM:DTIL
NasdaqCM:DTILBiotechs

Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative

Precision BioSciences (DTIL) closed out FY 2025 with Q4 revenue of US$34.2 million and Basic EPS of US$1.01, alongside earnings from discontinued operations of US$0.9 million and net income excluding extra items of US$19.2 million. Over recent quarters, the company has seen revenue range from US$0.6 million in Q4 2024 to US$34.2 million in Q4 2025. Over the same period, quarterly Basic EPS has moved from a loss of US$2.22 in Q4 2024 to a profit of US$1.01 in Q4 2025. This sets up an earnings...
NYSE:AIZ
NYSE:AIZInsurance

The Bull Case For Assurant (AIZ) Could Change Following Strong Q4 Beat And 2026 Outlook Update

Assurant, Inc. reported fourth-quarter 2025 net operating income and revenue above analyst estimates, driven by higher premiums and growth in its Global Housing and Global Lifestyle segments, and outlined 2026 adjusted EBITDA expectations that are consistent with or higher than 2025 alongside continued capital returns to shareholders. Separately, Assurant expanded access to its Reynolds and Reynolds docuPAD eContracting training program and announced that experienced financial services...
NYSE:TIC
NYSE:TICProfessional Services

TIC Solutions CEO Change And US$200m Buyback Reframe Turnaround Story

TIC Solutions (NYSE:TIC) has appointed Ben Heraud as its new CEO, succeeding long-serving leader Tal Pizzey. The company has also launched a $200 million share repurchase program. These changes were recently announced and have not been widely discussed in prior coverage. TIC Solutions is making these moves at a time when its share price is $7.25, with the stock showing a 40.3% decline over the past year and a 26.7% decline year to date. The new leadership and buyback plan arrive against...
NasdaqGS:EVCM
NasdaqGS:EVCMSoftware

EverCommerce (EVCM) Profitability Milestone Tests Bullish Narratives On Margin Sustainability

EverCommerce (EVCM) has wrapped up FY 2025 with fourth quarter revenue of US$151.2 million and basic EPS of US$0.03, alongside net income from ongoing operations of US$5.7 million. This caps a trailing twelve month period with revenue of US$588.9 million and EPS of US$0.10. Over recent quarters the company has seen revenue range from US$142.3 million to US$151.2 million, with quarterly EPS between US$0.01 and US$0.03. Over the same period, trailing twelve month net income from ongoing...
NYSE:FVRR
NYSE:FVRRProfessional Services

Is Fiverr (FVRR) Pricing Reflect Recent Share Slump Accurately

If you are wondering whether Fiverr International's current share price reflects its true worth, you are not alone. This article will walk you through what the numbers are actually saying about value. The stock has seen sizeable declines recently, with a 7.7% fall over the last week, a 27.6% decline over the last month, a 46.8% drop year to date, and a 59.2% decline over the past year. This extends a 68.5% and 95.3% fall across the last 3 and 5 years respectively. Recent attention on Fiverr...
NYSE:RH
NYSE:RHSpecialty Retail

Does RH (NYSE:RH) Share Price Slump Present A Valuation Opportunity?

If you are wondering whether RH's current share price reflects its true worth, you are not alone. This article will walk through what the numbers are saying about the stock's value today. RH shares last closed at US$128.37, after returns of a 9.7% decline over 7 days, a 35.8% decline over 30 days, a 33.6% decline year to date, a 43.0% decline over 1 year, a 47.9% decline over 3 years and a 75.1% decline over 5 years. Recent coverage around RH has focused on how the company is positioned...
NYSE:DCI
NYSE:DCIMachinery

Donaldson Acquisition Of Facet Shifts Focus Toward Critical Filtration Growth

Donaldson Company (NYSE:DCI) has agreed to acquire Facet, a provider of filtration solutions for aerospace, defense, and power generation. The deal is intended to expand Donaldson's product lineup and deepen its presence in durable end markets tied to critical infrastructure and equipment. The acquisition adds exposure to customers that require highly technical filtration in mission critical applications. Donaldson Company focuses on filtration technologies across industrial, engine, and...
NYSE:DELL
NYSE:DELLTech

Has Dell Technologies (DELL) Run Too Far After Its Recent Share Price Surge?

Wondering if Dell Technologies at around US$151.62 is still fairly priced, starting to look expensive, or offering value? This article is designed to help you frame that question clearly. The stock has seen strong momentum recently, with returns of 3.5% over 7 days, 22.1% over 30 days, 18.6% year to date, 61.4% over 1 year and 332.1% over 3 years. That naturally raises questions about what is already priced in. Recent coverage has focused on Dell as a key name in large scale computing and...
NYSE:OWL
NYSE:OWLCapital Markets

Is Blue Owl Capital (OWL) Pricing Make Sense After 1-Year 51.8% Share Price Decline

If you are wondering whether Blue Owl Capital's share price now reflects good value or just fresh risks, you are not alone. This article is here to unpack that question clearly. Over the short term the stock has seen sharp moves, with a 7 day return of an 11.5% decline, a 30 day return of a 30.6% decline and a year to date return of a 42.8% decline, while the 1 year return sits at a 51.8% decline compared to a 6.4% gain over 5 years and a 1.9% decline over 3 years. Recent headlines around...
NYSE:THG
NYSE:THGInsurance

Evaluating Hanover Insurance Group (THG) After Recent Share Swings And An Undervaluation Narrative

Event context and recent share performance Hanover Insurance Group (THG) has been on investors’ radar after recent share swings, including a roughly 6% decline over the past 3 months and a small gain over the past month. See our latest analysis for Hanover Insurance Group. At a share price of US$173.39, Hanover Insurance Group’s recent 1 day and 7 day share price declines sit against a modest 1 year total shareholder return of 4.5% and a strong 3 year total shareholder return of 53.4%. This...
OTCPK:BUKS
OTCPK:BUKSAerospace & Defense

Butler National (OTCPK:BUKS) Margin Expansion Reinforces Bullish Earnings Narratives In Q3 2026

Butler National (BUKS) has reported Q3 2026 revenue of US$26.9 million and basic EPS of US$0.10, set against trailing twelve month revenue of US$91.9 million and EPS of US$0.30 that came with 44.1% earnings growth and a 21.4% net margin over the past year. The company has seen quarterly revenue move from US$21.2 million in Q3 2025 to US$26.9 million in Q3 2026 and basic EPS from US$0.05 to US$0.10 across the same periods, with trailing net income reaching US$19.7 million, which positions the...
NasdaqGM:VITL
NasdaqGM:VITLFood

Why Vital Farms (VITL) Is Down 13.5% After Earnings Miss And Securities Probes News And What's Next

In recent weeks, Vital Farms reported weaker-than-expected quarterly earnings, prompting multiple law firms to launch securities investigations while the stock touched a new 52-week low and sector-wide pressures weighed on sentiment. Amid these legal probes and analyst concerns, Director Karl Khoury’s purchase of 5,000 additional shares stands out as a contrasting insider confidence signal. We’ll now examine how the earnings disappointment and resulting legal investigations might reshape...
NasdaqGS:TNYA
NasdaqGS:TNYABiotechs

How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story

In early March 2026, Tenaya Therapeutics reported a narrower full-year 2025 net loss of US$90.6 million and highlighted new preclinical data for TN-301 in Duchenne muscular dystrophy alongside a research collaboration with Alnylam Pharmaceuticals on up to 15 cardiovascular gene targets that could yield as much as US$1.13 billion in milestones. Together, these updates underscore how Tenaya is pairing emerging HDAC6 science in DMD and heart failure with a genetically guided partnership model...
NasdaqGS:CAPR
NasdaqGS:CAPRBiotechs

Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative

Capricor Therapeutics (CAPR) has just posted its FY 2025 first half results with total revenue of US$0 million and a basic EPS loss of US$1.10, while trailing twelve month revenue sits at US$13.39 million with a basic EPS loss of US$1.66. Over recent periods, the company has reported revenue of US$8.88 million and US$13.39 million across the two halves of FY 2024, alongside basic EPS losses of US$0.66 and US$0.51. This provides context for how current margins remain under pressure. With...
NYSE:HESM
NYSE:HESMOil and Gas

A Look At Hess Midstream (HESM) Valuation After New Share Buyback And Repurchase Agreement

Why Hess Midstream (HESM) is back on investor radars Hess Midstream (HESM) is drawing fresh attention after its board authorized a new buyback plan, and the partnership signed a repurchase agreement with JPMorgan to retire up to US$42 million of Class A shares. See our latest analysis for Hess Midstream. At a share price of US$38.99, Hess Midstream has recorded a 7.12% 1 month share price return and 11.94% 3 month share price return. Its 5 year total shareholder return of 166.77% contrasts...
NYSE:CSTM
NYSE:CSTMMetals and Mining

Constellium Buyback Targets Dilution While Shares Trade Below Valuation Estimates

Constellium (NYSE:CSTM) has announced a new share repurchase program of up to $300 million, authorized through the end of 2028. The new program replaces the previous buyback authorization. Constellium intends to use some repurchased shares to settle employee equity obligations, aiming to limit future dilution for shareholders. Constellium, trading at $24.61, has laid out a fresh $300 million buyback plan that directly addresses dilution, which many shareholders watch closely. The stock has...
NasdaqGM:OBIO
NasdaqGM:OBIOMedical Equipment

Orchestra BioMed (OBIO) First Profitable Quarter Tests Bearish Unprofitability Narrative

Orchestra BioMed Holdings (OBIO) just posted a sharp step up in activity for FY 2025, with fourth quarter revenue at US$30.9 million and basic EPS of US$0.10, compared with a full year where trailing twelve month revenue sat at US$33.5 million and EPS on that basis was a loss of US$1.11. The company has seen revenue move from quarterly levels below US$1 million through most of the year to the current US$30.9 million print, while quarterly basic EPS shifted from losses between US$0.49 and...
NasdaqGS:OLED
NasdaqGS:OLEDSemiconductor

Has Universal Display (OLED) Share Slide Created A Valuation Opportunity In OLED Materials?

If you have been wondering whether Universal Display's current share price reflects its true worth, you are not alone. This article aims to unpack that question clearly. The stock last closed at US$94.07, and returns of a 3.1% decline over 7 days, a 28.8% decline over 30 days, and a 22.8% decline year to date, as well as a 36.6% decline over 1 year, a 31.9% decline over 3 years, and a 57.2% decline over 5 years, may have reset expectations and risk perceptions for many investors. Recent news...
NasdaqGS:NWBI
NasdaqGS:NWBIBanks

CEO Buying And Quarterly Results Shape Northwest Bancshares Valuation Story

Northwest Bancshares (NasdaqGS:NWBI) President and CEO Louis J. Torchio recently acquired additional company shares, increasing his personal stake. The insider purchase took place around the time the bank reported strong fourth quarter financial results. The quarter featured earnings and revenue that were ahead of prior expectations, alongside the insider buying activity. Northwest Bancshares is a regional financial institution focused on community banking services, including deposits,...
NYSE:USAC
NYSE:USACEnergy Services

USA Compression Partners Expands Compression Platform With J W Power Acquisition

USA Compression Partners (NYSE:USAC) has agreed to acquire J-W Power, expanding its contract compression fleet and specialty manufacturing capabilities. The deal is positioned around asset repricing opportunities and deeper participation in compression equipment manufacturing. Management is framing the combination as a way to serve rising demand tied to LNG infrastructure and power needs from AI focused data centers. Industry capacity remains tight, with longer lead times for new compression...